Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
300 articles
A Phase 3 trial investigates whether the GLP-1 drug liraglutide can slow cognitive decline in T2DM patients at elevated Alzheimer's risk.
Sleep-wake patterns measured by wearables significantly predict dementia risk in 57,000+ older adults, matching the predictive power of genetic testing.
Researchers test a quantile-aggregation approach that may improve how Alzheimer's clinical trials detect treatment effects.
A spatial proteomics platform profiled 700,000+ brain cells, identifying a microglial subset that clusters around amyloid-β plaques in Alzheimer's disease.
A new deep learning model from UCSF predicts Alzheimer's diagnosis and cognitive trajectories from one MRI scan—no expensive multimodal imaging required.
A new tool that boosts mitochondrial activity in neurons restored memory in dementia mice, suggesting energy failure drives Alzheimer's symptoms.
27-Hydroxycholesterol triggers microglial senescence through iron dysregulation, and the iron chelator deferoxamine reverses the damage.
Cannabis use is surging among adults over 65, but Stanford Medicine specialists say today's potent marijuana carries serious, underestimated health risks.
Applied Cognition tests a wearable device that tracks glymphatic function overnight, comparing it to MRI, EEG, and blood biomarkers.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
Specific AQP4 genetic variants alter glymphatic drainage efficiency, directly influencing motor symptom severity and progression in early Parkinson's disease.
A landmark RCT tests whether hearing aids can protect brain health in 977 older adults over 3 years.
